Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...